Archive for December 2017

Allergy shots Effective for older Patients too

Recent years have seen an increase in those suffering from allergies, including baby boomers. And because older people tend to have additional chronic diseases, diagnosis and management of allergic rhinitis (hay fever) can be a challenge. A new study shows immunotherapy (allergy shots) reduced symptoms by 55 percent after three years of therapy, and decreased the amount of medication needed for relief of symptoms by 64 percent.

“Older people who suffer from hay fever may have health challenges that younger people do not,” said allergist Ira Finegold, MD, ACAAI past president. “Hay fever is often ignored in older patients as a less significant health problem because of diseases such as asthma, coronary heart disease, depression and high blood pressure. Also, some baby boomers might not realize they have allergies, and their physicians might not suggest allergy shots. The research indicated that allergy shots were extremely effective for this group.”

Although the guidelines for the diagnosis and treatment of allergic diseases rarely focus on older patients, according to the Polish study, hay fever is more common in patients over 65 years of age.

The study authors state the results of the study indicate an aging immune system doesn’t significantly influence the effectiveness of immunotherapy.


FDA Clears First Epinephrine Autoinjector for Infants

The US Food and Drug Administration (FDA) has approved the first and only epinephrine autoinjector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and children weighing 16.5 to 33 pounds (7.5 to 15 kg), according to a company statement.

Auvi-Q is a compact epinephrine auto-injector with industry-first features, including a voice prompt system that guides a user with step-by-step instructions through the delivery process, and a needle that automatically retracts following administration. The new 0.1 mg-dose epinephrine auto-injector has a shorter needle length and lower dose of epinephrine than current FDA approved 0.15 mg and 0.3 mg epinephrine auto-injectors.